Literature DB >> 21878452

Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture-recapture method.

O Fernández1, V Fernández, M Guerrero, A León, J C López-Madrona, A Alonso, R Bustamante, J A Tamayo, F Romero, M Bravo, G Luque, L García, G Sanchís, C San Roman, M Romero, M Papais-Alvarenga, E de Ramon.   

Abstract

BACKGROUND: Although not definitively proven, there is commonly accepted to be a latitudinal gradient in the distribution of multiple sclerosis (MS), which is more frequent in temperate zones. The European Mediterranean countries are situated in a zone of median frequency, although ever increasing figures have been noted in the last decades.
OBJECTIVE: The objective of this study was to assess the current prevalence rate of MS in the province of Malaga, Southern Spain.
METHODS: The capture-recapture method (CRM) uses independent sources of data and permits the number of non-registered cases of a given disease to be estimated, and by doing so, to avoid ascertainment bias.
RESULTS: Use of this method showed the estimated prevalence rate of MS in the province of Malaga, Southern Spain, to be 125/10(5) (95% confidence interval: 102/10(5)-169/10(5)), higher than the figures published previously.
CONCLUSIONS: Although we recognize that these data need to be confirmed in further studies and in other areas of the country using a similar method, we believe this study is the first to find such high figure of prevalence, being very similar to the figures reported in recent years in other southern European countries.

Entities:  

Mesh:

Year:  2011        PMID: 21878452     DOI: 10.1177/1352458511421917

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  12 in total

1.  Incidence of multiple sclerosis in Northern Lisbon, Portugal: 1998-2007.

Authors:  Joao de Sá; Enrique Alcalde-Cabero; Javier Almazán-Isla; Fernando García-López; Jesús de Pedro-Cuesta
Journal:  BMC Neurol       Date:  2014-12-21       Impact factor: 2.474

2.  Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.

Authors:  Rainel Sánchez-de la Rosa; Laura García-Bujalance; José Meca-Lallana
Journal:  Health Econ Rev       Date:  2015-10-16

3.  Long-term epidemiology of multiple sclerosis in the Northern Seville District.

Authors:  Guillermo Izquierdo; Ana Venegas; Carmen Sanabria; Guillermo Navarro
Journal:  Acta Neurol Scand       Date:  2015-02-04       Impact factor: 3.209

4.  Impact on healthcare resource utilization of multiple sclerosis in Spain.

Authors:  Antoni Sicras-Mainar; Elena Ruíz-Beato; Ruth Navarro-Artieda; Jorge Maurino
Journal:  BMC Health Serv Res       Date:  2017-12-29       Impact factor: 2.655

5.  Is the association between health-related quality of life and fatigue mediated by depression in patients with multiple sclerosis? A Spanish cross-sectional study.

Authors:  Juan J Fernández-Muñoz; Margarita Cigarán-Méndez; Esperanza Navarro-Pardo; Marta Pérez-de-Heredia-Torres; Paula Parás-Bravo; César Fernández-de-Las-Peñas
Journal:  BMJ Open       Date:  2018-01-23       Impact factor: 2.692

6.  Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain.

Authors:  Antoni Sicras-Mainar; Elena Ruíz-Beato; Ruth Navarro-Artieda; Jorge Maurino
Journal:  BMC Neurol       Date:  2017-07-17       Impact factor: 2.474

7.  Multiple sclerosis epidemiology in Latin America: An updated survey.

Authors:  Edgardo Cristiano; Juan Ignacio Rojas
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-06-13

8.  The epidemiology of multiple sclerosis in the entre Douro e Vouga region of northern Portugal: a multisource population-based study.

Authors:  Mariana Branco; Ivânia Alves; Ana Martins da Silva; Joaquim Pinheiro; Maria José Sá; Inês Correia; Lívia Sousa; Eva Brandão; Carlos Veira; Bernardo Gomes; Luis Ruano
Journal:  BMC Neurol       Date:  2020-05-19       Impact factor: 2.474

9.  Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain.

Authors:  Rainel Sanchez-de la Rosa; Eliazar Sabater; Miguel A Casado
Journal:  Health Econ Rev       Date:  2013-05-07

10.  Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.

Authors:  O Fernández; R Arroyo; S Martínez-Yélamos; M Marco; J A García Merino; D Muñoz; E Merino; A Roque
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.